• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by VivoSim Labs Inc.

    11/3/25 4:07:49 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIVS alert in real time by email
    DEFA14A 1 vivs_defa_14a_2025.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material under §240.14a-12

    VivoSim Labs, Inc.

    (Name of Registrant as Specified In Its Charter)

    Not Applicable

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

     

     

     

     

    ☐

    Fee paid previously with preliminary materials.

     

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     


     

    img22547606_0.jpg

    Your Vote Counts! ORGANOVO HOLDINGS, INC. 2023 Annual Meeting Vote by October 30, 2023 11:59 PM ET ORGANOVO HOLDINGS, INC. 11555 SORRENTO VALLEY ROAD, SUITE 100 SAN DIEGO, CA 92121 V23261-P98852 You invested in ORGANOVO HOLDINGS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on October 31, 2023. Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 17, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote Virtually at the Meeting* October 31, 2023 9:00 a.m. Pacific Time Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/ONVO2023 *Please check the meeting materials for any special requirements for meeting attendance. V1.2

     

     


     

    img22547606_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. To elect each of Keith Murphy and Adam Stern as a Class III director to hold office until the 2026 Annual Meeting of Stockholders and until his respective successor is elected and qualified. Nominees: For 1a. Keith Murphy 1b. Adam Stern For 2. To ratify the appointment of Rosenberg Rich Baker Berman P.A. as our independent registered public accounting firm for the fiscal year ending March 31, 2024. For For 3. To approve, on an advisory basis, the compensation of our named executive officers. For 4. To approve the Organovo Holdings, Inc. 2023 Employee Stock Purchase Plan. 5. To approve an amendment to our Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V23262-P98852

     


    Get the next $VIVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Gobel David

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    11/19/25 4:01:04 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Lialin Tony Serge

    4 - VivoSim Labs, INC. (0001497253) (Issuer)

    8/21/25 8:45:18 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Lialin Tony Serge

    3 - VivoSim Labs, INC. (0001497253) (Issuer)

    8/21/25 8:41:01 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    SEC Filings

    View All

    SEC Form 10-Q filed by VivoSim Labs Inc.

    10-Q - VivoSim Labs, INC. (0001497253) (Filer)

    11/6/25 4:08:13 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by VivoSim Labs Inc.

    DEFA14A - VivoSim Labs, INC. (0001497253) (Filer)

    11/3/25 4:07:49 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by VivoSim Labs Inc.

    DEF 14A - VivoSim Labs, INC. (0001497253) (Filer)

    11/3/25 4:06:32 PM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

    SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim") announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon "Poster of Distinction" award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD). The Company's award-winning research showcased a physiologically relevant system built from primary human cells derived from both healthy donors and patients with Ulcer

    5/13/25 8:05:27 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIVS
    Leadership Updates

    Live Leadership Updates

    View All

    VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

    SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players

    8/14/25 8:05:12 AM ET
    $VIVS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care